Latest news

25 Apr 2019 News
One in 10 cancer patients denied drugs recommended by their doctor, study finds
24 Apr 2019 Renal
Keytruda® in combination with Inlyta® receives US FDA approval for renal cell carcinoma
16 Apr 2019 News
Oncology conferences and event highlights: April–June 2019
16 Apr 2019 Lung
US FDA expands the approval of Keytruda® in Stage III NSCLC

Video

View all videos

13 Feb 2019 Lung
Tumor clonality and resistance mechanisms in EGFR mutation-positive NSCLC: implications for therapeutic sequencing

Video

View all videos

Features

Stay up to date

Upcoming event

Gastrointestinal Cancers Symposium

January 17, 2019 – January 19, 2019

CA, USA

View all

Upcoming event

International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer

February 9, 2019 – February 11, 2019

Kyoto, Japan

View all

Tweets

Oncology Central @OncologyCentral·

A recent study has found one in 10 cancer patients are denied drugs recommended by their doctor. Find out about the @ICR_London manifesto that is calling for action on cancer drug access https://t.co/aIUwvA38t7

View all

Jobs

Connecting talent with opportunity. View our featured jobs

View all

Our mission statement

At Oncology Central we are dedicated to advancing oncology by publishing trusted, engaging and insightful resources for the global oncology community.

Learn more

One in 10 cancer patients denied drugs recommended by their doctor, study finds

Keytruda® in combination with Inlyta® receives US FDA approval for renal cell carcinoma

Oncology conferences and event highlights: April–June 2019

US FDA expands the approval of Keytruda® in Stage III NSCLC

Spotlight survey on organoids on oncology

Pembrolizumab for small-cell lung cancer: an interview with Hyun Cheol Chung

Pharma, President, Patients: the cancer cost conundrum

Lung squamous cell carcinoma: key molecular player discovered

Colorectal cancer screening age to be lowered to 50 in England

Exploring the Thyroid Imaging Reporting and Data System (TI-RADS): an interview with Franklin Tessler

Q&A follow up: A closer look at physical activity and cancer prevention

A closer look at: physical activity and cancer prevention

Induction of receptor tyrosine kinase signaling by sera isolated from patients with lung adenocarcinoma

Video

Tumor clonality and resistance mechanisms in EGFR mutation-positive NSCLC: implications for therapeutic sequencing

Video

Login

Latest news

One in 10 cancer patients denied drugs recommended by their doctor, study finds

Keytruda® in combination with Inlyta® receives US FDA approval for renal cell carcinoma

Oncology conferences and event highlights: April–June 2019

US FDA expands the approval of Keytruda® in Stage III NSCLC

Featured articles

Spotlight survey on organoids on oncology

Pembrolizumab for small-cell lung cancer: an interview with Hyun Cheol Chung

Pharma, President, Patients: the cancer cost conundrum

Lung squamous cell carcinoma: key molecular player discovered

Colorectal cancer screening age to be lowered to 50 in England

Exploring the Thyroid Imaging Reporting and Data System (TI-RADS): an interview with Franklin Tessler

Q&A follow up: A closer look at physical activity and cancer prevention

A closer look at: physical activity and cancer prevention

Induction of receptor tyrosine kinase signaling by sera isolated from patients with lung adenocarcinoma

Video

Tumor clonality and resistance mechanisms in EGFR mutation-positive NSCLC: implications for therapeutic sequencing

Video

HTX-019 2-min injection shows promise as an alternative method of administration to prevent CINV

Unraveling the tumor biology of pancreatic cancer with Harpreet Wasan

Tumor clonality and resistance mechanisms in EGFR mutation-positive NSCLC: implications for therapeutic sequencing

Emerging treatment options for pancreatic cancer with Thomas Seufferlein

Tamoxifen, SERMs and sustainable medicine

Seven challenges in immuno-oncology

Features

Interviews

Spotlights

Journal articles

Stay up to date

Oncology Central Newsletter